Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2021 16:05 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
January 19, 2021 08:30 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
December 16, 2020 18:43 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
December 15, 2020 16:01 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock

FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
December 14, 2020 08:30 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)

FLORHAM PARK, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
November 30, 2020 16:05 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
November 27, 2020 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
November 19, 2020 16:05 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Host Virtual Investor Day

Event to be webcast on Monday, December 14, 2020 at 1:00 PM (ET) FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage...
November 13, 2020 16:05 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
November 10, 2020 16:05 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials

Pivotal Phase 3 PHALCON-EE trial enrollment expected to complete before year-end 2020; top-line results expected in the second half of 2021Pivotal Phase 3 PHALCON-HP trial enrollment expected to...